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ABSTRACT
INTRODUCTION: According to the consensus and the recommendations of the European Neuroendo-
crine Tumor Society (ENETS), the annual incidence rate of neuroendocrine appendicular tumours is 0.15-
0.6/100000. They are little more common in women aged between 40 and 50 years. These neoplasms amount 
to 30-80% of all appendicular tumours. Their evolution is, usually, asymptomatic and they are diagnosed 
accidentally during conventional or laparoscopic appendectomy. In the past, the surgical approach used to 
depend on tumour localization. At presence, this localization is not a decisive factor in the choice of a sur-
gical approach. Our purpose was to demonstrate the consensus guideline and the recommendations of EN-
ETS 2017 for surgical procedures in neuroendocrine appendicular neoplasms and to analyze the difference 
in the survival rate following various surgical interventions.
MATERIAL AND METHODS: Literature overview included studies dealing with the surgical treatment of 
the neuroendocrine appendicular neoplasms including the most recent consensus guideline of ENETS 2017 
on the topic.
RESULTS: Our analysis revealed that according to ENETS 2017, tumour size, localization and tumour cell 
invasion into the mesoappendix determined the type and volume of surgical intervention. For tumours less 
than 1 cm (T1 according to ENETS pathological classification), a simple appendectomy was recommended. 
In T1 tumours, this surgical procedure resulted in 100% survival rate.
CONCLUSION: ENETS 2017 recommends to observe the last established consensus guideline despite the fact 
that the studies up-to-now do not show any significant difference in the survival rate after appendectomy 
because of a neuroendocrine tumour of the appendix and right hemicolectomy.  Scr Sci Med 2017;49(3):11-14
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INTRODUCTION
The annual incidence rate of neuroendocrine 
appendicular tumours is 0.15-0.6/100000 (1). They 
represent 30 to 80% of all appendicular neoplasms 
(1). They are little more common in women aged 
between 40 and 50 years. They are also observed in 
children aged between 4.5 and 19.5 years, however, 
there is no standardized population-based data for 
this age group yet. The prognosis of these neoplasms 
is good. In a series of studies, five-year survival rate 
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is 100% or close to 100% in highly-differentiated tu-
mours (2,3). In large cohort studies involving tumors 
of varying degrees of differentiation, this rate is be-
tween 70% and 85% (4). However, it is much lower in 
patients at advanced stage of the disease and present-
ing with distant metastases. In such cases, it ranges 
from 12% to 28%.
Seventy percent of neuroendocrine appendicu-
lar tumours are located at the tip of the appendix (1). 
Their evolution is, usually, asymptomatic and they 
are diagnosed accidentally during conventional or 
laparoscopic appendectomy (5). They persist either 
asymptomatically, or in the presence of metastasis. 
Besides they may exhibit symptoms associated with 
the localization of the metastases. Carcinoid syn-
drome is rarely observed with these neoplasms (6). 
There are no imaging studies characterized by high 
informative and specific probative value.
Somatostatin receptor imaging and positron 
emission tomography can be used to prove distant 
metastases. Chromogranin A is used as a laboratory 
tumour marker for an advanced disease, however, it 
is not validated for diagnosis and follow-up of these 
neoplasms yet.
According to consensus decisions and recom-
mendations from the European Neuroendocrine Tu-
mor Society (ENETS) 2011 and 2017, the size, local-
ization and the tumor cell invasion into the mesoap-
pendix determine the surgical therapy. Two surgical 
techniques are applicable to these tumours: simple 
appendectomy and oncological right hemicolectomy 
(1). The most recent recommendations and consen-
sus guideline of March 2017 set out precise selection 
criteria for specific surgery which is the most appro-
priate one for these patients.
Our purpose is to present the consensus guide-
line and the recommendations of ENETS 2017 for 
surgical procedures in neuroendocrine appendicular 
neoplasms and to analyze the difference in the sur-
vival rate following various surgical interventions.
MATERIAL AND METHODS
Literature overview includes studies about sur-
gical treatment of neuroendocrine neoplasms of the 
appendix including the last consensus guideline of 
ENETS 2017 on the topic.
RESULTS 
Our analysis reveals that according to ENETS 
2017, tumour size, localization and tumour cell inva-
sion into the mesoappendix determine the type and 
volume of surgical intervention. For tumours less 
than 1 cm (T1 according to ENETS pathological clas-
sification), a simple appendectomy is recommended. 
In T1 tumours, this surgical procedure leads to 100% 
survival rate.
DISCUSSION 
Tumours sized between 1 and 2 cm (T2) prove 
to be a challenge for surgeons because of the risk of 
metastasis and/or relapse. Most often, metastases oc-
cur in tumours larger than 1.5 cm (7). Tumours sized 
above 2 cm (T3) are rare, less than 10% of all the neu-
roendocrine appendicular neoplasms. The risk of 
metastasis in T2 tumours reaches up to 40% (8,9). 
The European Neuroendocrine Tumors Society rec-
ommends oncological right hemiclectomy in T3 tu-
mors. The tumours emerging from the appendix 
and infiltrating adjacent structures (T4) require sys-
temic oncological evaluation including initial right 
hemicolectomy.
Sixty to 75% of the neuroendocrine appendicu-
lar neoplasms are located at the tip, 5 to 20% of them 
are placed in the middle, and only 10% of them are 
at the base of the appendix. There is no strict correla-
tion between survival rate and tumour localization, 
however, it is assumed that the tumours at the ap-
pendicular base are more prone to metastasis (10,11).
An invasion into the mesoappendix is observed 
in up to 20% of adults and in up to 40% in children 
(12,13). An invasion of more than 3 mm results in a 
more aggressive course of the disease.
The oncological right hemicolectomy is rec-
ommended for tumours sized above 2 cm. In T1 tu-
mours, the simple appendectomy is sufficient. How-
ever, this intervention is not sufficient in cases either 
when the tumour is located at the appendicular base, 
or when it infiltrates the mesoepithelium at a depth 
of more than 3 mm. In T2 tumours, lymph node lo-
cations as well as distant metastases are likely. There-
fore, the simple appendectomy in these tumours is 
not always radical and the recurrence is common, 
especially in young subjects. The risk of relapse in-
creases in tumours sized above 1.5 cm. 
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ENETS recommends oncological right hemico-
lectomy if one of the following criteria exists:
 moderately differentiated tumour (G2)
 vascular invasion (V1)
 lymphatic invasion (L1), and
 infiltration into the mesoappendix deeper than 
3 mm.
In T3 tumours, oncological right hemicolecto-
my is performed either as an initial surgical interven-
tion, or as a second intervention after initial appen-
dectomy. The neuroendocrine appendicular carcino-
mas (G3) are treated as adenocarcinomas.
ENETS 2017 assumes that in tumours less than 
2 cm, the appendectomy is sufficient, regardless of 
tumour location. Right hemicolectomy is justified 
only in cases of tumours sized 1 to 2 cm with posi-
tive or unclear resection margins, invasion into the 
mesoappendix, high proliferative index, or vascular 
invasion. Tumours sized more than 2 cm should be 
treated by oncological right hemicolectomy.
CONCLUSION
Well-sized neuroendocrine appendicular tu-
mours smaller than 1 cm do not require any follow-
up. For tumours sized between 1 and 2 cm, follow-
up is desirable, but not recommended. For tumours 
sized over 2 cm, mandatory follow-up at 6 and 12 
months and then once yearly is recommended, al-
though there is no strictly validated standard yet.
The neuroendocrine appendicular tumour is 
based on specific pathological and clinical criteria 
developed and recommended by the European Neu-
roendocrine Tumor Society. Despite currently avail-
able studies demonstrating the lack of significant 
difference in survival rates after appendetomy com-
pared to right hemicolectomy, ENETS 2017 recom-
mends to strictly observe the most recent established 
consensus.
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